-
Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study
•
Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in 2018, has released interim data from the 16-week mark in the Phase III QUARTZ3 study. The study is assessing the efficacy of the JAK1 inhibitor ivarmacitinib in patients with moderate to severe atopic dermatitis (AD).…
-
Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms
•
Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical equipment firms to set up joint ventures (JVs) with majority stakes controlled by the state-owned company. This strategic move aims to enhance Sinopharm’s capabilities in the medical equipment sector. Radiotherapy and Imaging Joint VenturesSinopharm’s subsidiary,…
-
BeiGene Marks Topping Off of New Biologics Facility in New Jersey
•
China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the “topping off” of construction at its new biologics manufacturing and R&D facility in Hopewell, New Jersey. The last piece of structural steel was laid at the site, signaling that construction is now expected to be…
-
Roche Partners with China Resource Medicine to Promote Xofluza in China
•
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource Medicine Commercial Holdings Ltd to jointly promote the anti-influenza drug Xofluza (baloxavir marboxil) in China. Under the agreement, Roche will continue to handle channel promotion for the drug in major hospitals, while CR Medicine Commercial…
-
Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination
•
China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme Inc. (NYSE: MRK) to assess the clinical effects of Jacobio’s CD73 monoclonal antibody (mAb) JAB-BX102 combined with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) in advanced solid tumors. No financial details were disclosed in the partnership agreement.…
-
Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s F-652 has been cleared to start a Phase II clinical trial for a new indication by China’s National Medical Products Administration (NMPA). The trial will assess F-652 as a treatment for alcoholic hepatitis (AH). Mechanism…
-
BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392
•
Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with US-based biotech OncoC4, securing global development and commercialization rights to OncoC4’s anti-CTLA-4 antibody ONC-392. Under the terms of the agreement, BioNTech will pay OncoC4 USD 200 million upfront, with further undisclosed development and commercial milestone…
-
Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology
•
Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi in a Series C+ financing round. The round was led by Source Code Capital, with contributions from CCB Private Equity Investment, E-town Capital, Founder H Fund, and Lotus Lake Capital. The funds will be used…
